An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis

Veronica Codullo, Helen M. Baldwin, Mark D. Singh, Alasdair R. Fraser, Catherine Wilson, Ashley Gilmour, Axel J. Hueber, Claudia Bonino, Iain B. McInnes, Carlomaurizio Montecucco, Gerard J. Graham

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objectives Systemic sclerosis (SSc) is characterised by vasculopathy, an aberrantly activated immune system and excessive extracellular matrix deposition. Inflammatory chemokines control migration of cells to sites of tissue damage; their removal from inflamed sites is essential for resolution of the inflammatory response. The atypical chemokine receptor D6 has a critical role in this physiological balance. To explore potential deregulation of this system in SSc, inflammatory chemokine and D6 expression were compared with that in healthy controls (HC). Methods Serum levels of inflammatory mediators were assessed by luminex analysis. Peripheral blood mononuclear cells (PBMCs) were used in molecular and immunocytochemical analysis. Platelet-rich plasma was collected and assessed by western blotting for D6 expression levels. Sex-matched HC were used for comparison. Results 72 patients with SSc and 30 HC were enrolled in the study. The chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL-8/CXCL8 were significantly increased in patients with SSc, regardless of disease subtype and phase. Quantitative PCR analysis revealed a significant 10-fold upregulation of D6 transcripts in patients with SSc compared with controls, and this was paralleledby increased D6 protein expression in the PBMCs of patients with SSc. Platelet lysates also showed strong D6 expression in patients with SSc but not in controls. Importantly, high levels of D6 expression correlated with reduced levels of its ligands in serum. Conclusions Inflammatory chemokines and the regulatory receptor D6 are significantly upregulated in SSc and high D6 levels are associated with lower systemic chemokine levels, indicating that some patients control systemic chemokine levels using D6. These results suggest that chemokines may represent a therapeutic target in SSc.

Original languageEnglish
Pages (from-to)1115-1121
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Systemic Scleroderma
Chemokines
Cytokines
Platelets
Blood
Blood Cells
Deregulation
Immune system
Interleukin-8
Platelet-Rich Plasma
Serum
Cells
Cell Movement
Tissue
Extracellular Matrix
Ligands
Immune System
Plasmas
Up-Regulation
Blood Platelets

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Codullo, V., Baldwin, H. M., Singh, M. D., Fraser, A. R., Wilson, C., Gilmour, A., ... Graham, G. J. (2011). An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Annals of the Rheumatic Diseases, 70(6), 1115-1121. https://doi.org/10.1136/ard.2010.137349

An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. / Codullo, Veronica; Baldwin, Helen M.; Singh, Mark D.; Fraser, Alasdair R.; Wilson, Catherine; Gilmour, Ashley; Hueber, Axel J.; Bonino, Claudia; McInnes, Iain B.; Montecucco, Carlomaurizio; Graham, Gerard J.

In: Annals of the Rheumatic Diseases, Vol. 70, No. 6, 06.2011, p. 1115-1121.

Research output: Contribution to journalArticle

Codullo, V, Baldwin, HM, Singh, MD, Fraser, AR, Wilson, C, Gilmour, A, Hueber, AJ, Bonino, C, McInnes, IB, Montecucco, C & Graham, GJ 2011, 'An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis', Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1115-1121. https://doi.org/10.1136/ard.2010.137349
Codullo, Veronica ; Baldwin, Helen M. ; Singh, Mark D. ; Fraser, Alasdair R. ; Wilson, Catherine ; Gilmour, Ashley ; Hueber, Axel J. ; Bonino, Claudia ; McInnes, Iain B. ; Montecucco, Carlomaurizio ; Graham, Gerard J. / An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. In: Annals of the Rheumatic Diseases. 2011 ; Vol. 70, No. 6. pp. 1115-1121.
@article{db56f1aa655d4b658b691e6601579c05,
title = "An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis",
abstract = "Objectives Systemic sclerosis (SSc) is characterised by vasculopathy, an aberrantly activated immune system and excessive extracellular matrix deposition. Inflammatory chemokines control migration of cells to sites of tissue damage; their removal from inflamed sites is essential for resolution of the inflammatory response. The atypical chemokine receptor D6 has a critical role in this physiological balance. To explore potential deregulation of this system in SSc, inflammatory chemokine and D6 expression were compared with that in healthy controls (HC). Methods Serum levels of inflammatory mediators were assessed by luminex analysis. Peripheral blood mononuclear cells (PBMCs) were used in molecular and immunocytochemical analysis. Platelet-rich plasma was collected and assessed by western blotting for D6 expression levels. Sex-matched HC were used for comparison. Results 72 patients with SSc and 30 HC were enrolled in the study. The chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL-8/CXCL8 were significantly increased in patients with SSc, regardless of disease subtype and phase. Quantitative PCR analysis revealed a significant 10-fold upregulation of D6 transcripts in patients with SSc compared with controls, and this was paralleledby increased D6 protein expression in the PBMCs of patients with SSc. Platelet lysates also showed strong D6 expression in patients with SSc but not in controls. Importantly, high levels of D6 expression correlated with reduced levels of its ligands in serum. Conclusions Inflammatory chemokines and the regulatory receptor D6 are significantly upregulated in SSc and high D6 levels are associated with lower systemic chemokine levels, indicating that some patients control systemic chemokine levels using D6. These results suggest that chemokines may represent a therapeutic target in SSc.",
author = "Veronica Codullo and Baldwin, {Helen M.} and Singh, {Mark D.} and Fraser, {Alasdair R.} and Catherine Wilson and Ashley Gilmour and Hueber, {Axel J.} and Claudia Bonino and McInnes, {Iain B.} and Carlomaurizio Montecucco and Graham, {Gerard J.}",
year = "2011",
month = "6",
doi = "10.1136/ard.2010.137349",
language = "English",
volume = "70",
pages = "1115--1121",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis

AU - Codullo, Veronica

AU - Baldwin, Helen M.

AU - Singh, Mark D.

AU - Fraser, Alasdair R.

AU - Wilson, Catherine

AU - Gilmour, Ashley

AU - Hueber, Axel J.

AU - Bonino, Claudia

AU - McInnes, Iain B.

AU - Montecucco, Carlomaurizio

AU - Graham, Gerard J.

PY - 2011/6

Y1 - 2011/6

N2 - Objectives Systemic sclerosis (SSc) is characterised by vasculopathy, an aberrantly activated immune system and excessive extracellular matrix deposition. Inflammatory chemokines control migration of cells to sites of tissue damage; their removal from inflamed sites is essential for resolution of the inflammatory response. The atypical chemokine receptor D6 has a critical role in this physiological balance. To explore potential deregulation of this system in SSc, inflammatory chemokine and D6 expression were compared with that in healthy controls (HC). Methods Serum levels of inflammatory mediators were assessed by luminex analysis. Peripheral blood mononuclear cells (PBMCs) were used in molecular and immunocytochemical analysis. Platelet-rich plasma was collected and assessed by western blotting for D6 expression levels. Sex-matched HC were used for comparison. Results 72 patients with SSc and 30 HC were enrolled in the study. The chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL-8/CXCL8 were significantly increased in patients with SSc, regardless of disease subtype and phase. Quantitative PCR analysis revealed a significant 10-fold upregulation of D6 transcripts in patients with SSc compared with controls, and this was paralleledby increased D6 protein expression in the PBMCs of patients with SSc. Platelet lysates also showed strong D6 expression in patients with SSc but not in controls. Importantly, high levels of D6 expression correlated with reduced levels of its ligands in serum. Conclusions Inflammatory chemokines and the regulatory receptor D6 are significantly upregulated in SSc and high D6 levels are associated with lower systemic chemokine levels, indicating that some patients control systemic chemokine levels using D6. These results suggest that chemokines may represent a therapeutic target in SSc.

AB - Objectives Systemic sclerosis (SSc) is characterised by vasculopathy, an aberrantly activated immune system and excessive extracellular matrix deposition. Inflammatory chemokines control migration of cells to sites of tissue damage; their removal from inflamed sites is essential for resolution of the inflammatory response. The atypical chemokine receptor D6 has a critical role in this physiological balance. To explore potential deregulation of this system in SSc, inflammatory chemokine and D6 expression were compared with that in healthy controls (HC). Methods Serum levels of inflammatory mediators were assessed by luminex analysis. Peripheral blood mononuclear cells (PBMCs) were used in molecular and immunocytochemical analysis. Platelet-rich plasma was collected and assessed by western blotting for D6 expression levels. Sex-matched HC were used for comparison. Results 72 patients with SSc and 30 HC were enrolled in the study. The chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL-8/CXCL8 were significantly increased in patients with SSc, regardless of disease subtype and phase. Quantitative PCR analysis revealed a significant 10-fold upregulation of D6 transcripts in patients with SSc compared with controls, and this was paralleledby increased D6 protein expression in the PBMCs of patients with SSc. Platelet lysates also showed strong D6 expression in patients with SSc but not in controls. Importantly, high levels of D6 expression correlated with reduced levels of its ligands in serum. Conclusions Inflammatory chemokines and the regulatory receptor D6 are significantly upregulated in SSc and high D6 levels are associated with lower systemic chemokine levels, indicating that some patients control systemic chemokine levels using D6. These results suggest that chemokines may represent a therapeutic target in SSc.

UR - http://www.scopus.com/inward/record.url?scp=79955802032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955802032&partnerID=8YFLogxK

U2 - 10.1136/ard.2010.137349

DO - 10.1136/ard.2010.137349

M3 - Article

C2 - 21285114

AN - SCOPUS:79955802032

VL - 70

SP - 1115

EP - 1121

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -